- Home
- CBAN vs FHTX Comparison
CBAN vs FHTX Comparison
Compare CBAN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- FHTX
- Stock Information
- Founded
- CBAN 1975
- FHTX 2015
- Country
- CBAN United States
- FHTX United States
- Employees
- CBAN N/A
- FHTX N/A
- Industry
- CBAN Major Banks
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- CBAN Finance
- FHTX Health Care
- Exchange
- CBAN Nasdaq
- FHTX Nasdaq
- Market Cap
- CBAN 279.6M
- FHTX 278.1M
- IPO Year
- CBAN 1998
- FHTX 2020
- Fundamental
- Price
- CBAN $17.06
- FHTX $5.77
- Analyst Decision
- CBAN
- FHTX Strong Buy
- Analyst Count
- CBAN 0
- FHTX 6
- Target Price
- CBAN N/A
- FHTX $11.33
- AVG Volume (30 Days)
- CBAN 57.7K
- FHTX 84.1K
- Earning Date
- CBAN 10-22-2025
- FHTX 11-03-2025
- Dividend Yield
- CBAN 2.69%
- FHTX N/A
- EPS Growth
- CBAN 24.13
- FHTX N/A
- EPS
- CBAN 1.57
- FHTX N/A
- Revenue
- CBAN $118,533,000.00
- FHTX $24,173,000.00
- Revenue This Year
- CBAN $21.97
- FHTX $43.75
- Revenue Next Year
- CBAN $27.53
- FHTX $1.27
- P/E Ratio
- CBAN $10.89
- FHTX N/A
- Revenue Growth
- CBAN 8.33
- FHTX N/A
- 52 Week Low
- CBAN $13.99
- FHTX $2.95
- 52 Week High
- CBAN $18.49
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- CBAN 54.44
- FHTX 58.68
- Support Level
- CBAN $16.90
- FHTX $5.14
- Resistance Level
- CBAN $17.50
- FHTX $5.46
- Average True Range (ATR)
- CBAN 0.35
- FHTX 0.37
- MACD
- CBAN 0.05
- FHTX 0.05
- Stochastic Oscillator
- CBAN 65.52
- FHTX 99.03
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.